The legacy of general health and science information has long emphasized the importance of understanding medication side effects as part of patient safety. Within this broad context, the focus on bone health and therapeutic interventions has been a consistent theme, particularly regarding treatments for conditions like osteoporosis. Fosamax, a bisphosphonate medication, has been widely studied and prescribed for its role in increasing bone density and reducing fracture risk. Over time, clinical observations and post-marketing surveillance have identified a rare but serious adverse event: osteonecrosis of the jaw (ONJ). This condition, characterized by exposed bone in the maxillofacial region, has been linked to Fosamax exposure, prompting a shift in how clinicians assess risk-benefit profiles for patients.
Transitioning from this general health perspective to an occupational exposure concern requires a careful pivot. While the initial focus was on patients receiving therapeutic doses, the same biological mechanisms that raise ONJ risk in clinical settings may also apply to individuals with incidental or chronic exposure in non-clinical environments. For instance, workers involved in the manufacturing, handling, or disposal of Fosamax or related compounds could face inhalation or dermal contact with the active ingredient. This occupational dimension introduces a new layer of risk assessment, where exposure levels, duration, and routes differ from prescribed use. Thus, the bridge from general health information to occupational concern lies in recognizing that the same substance linked to ONJ in patients may pose analogous risks in workplace settings, warranting targeted surveillance and preventive measures.
Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its use has been associated with osteonecrosis of the jaw (ONJ), a condition characterized by exposed, non-healing bone in the maxillofacial region. ONJ can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The condition is also reported with the combination product Fosamax Plus D (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Clinical presentation of ONJ typically involves exposed bone in the jaw that persists for more than eight weeks, often accompanied by pain, swelling, infection, or drainage. Diagnosis is primarily clinical, based on visual examination and patient history, and may be supported by imaging studies to rule out other conditions such as metastatic disease or osteomyelitis. The condition can lead to significant morbidity, including difficulty eating, speaking, and maintaining oral hygiene.
The mechanistic pathways linking Fosamax to ONJ are not fully understood but are believed to involve the drug's potent inhibition of osteoclast-mediated bone resorption. Bisphosphonates like alendronate accumulate in bone tissue, particularly at sites of high turnover, such as the jaw. This accumulation can suppress normal bone remodeling, leading to microdamage accumulation and impaired healing after dental procedures or minor trauma. Additionally, bisphosphonates may have anti-angiogenic effects, reducing blood supply to the jawbone, and may alter immune responses, increasing susceptibility to infection. Multiscale characterization of jawbone in animal models has provided comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). Studies in estrogen-deficient rats treated with alendronate have examined effects on the jawbone, including mechanical stability of teeth, tissue mineral density distribution, and nanoindentation properties (https://pubmed.ncbi.nlm.nih.gov/40345077/). Risk factors for developing ONJ in patients taking Fosamax include invasive dental procedures such as tooth extraction, dental implants, or boney surgery; diagnosis of cancer; concomitant therapies including chemotherapy, corticosteroids, and angiogenesis inhibitors; poor oral hygiene; and co-morbid disorders such as periodontal disease, pre-existing dental disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).
The timeline between exposure to Fosamax and documented harm from ONJ is variable. The time to onset of symptoms ranged from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the medication, but a subset experienced recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Adequacy of warnings regarding Fosamax and ONJ is addressed in the prescribing information. The label includes a specific warning under section 5.4 titled 'Osteonecrosis of the Jaw,' which describes the condition, associated risk factors, and clinical considerations (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The label also notes that the optimal duration of use has not been determined and that for patients at low risk for fracture, drug discontinuation after 3 to 5 years of use may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, the label does not provide specific guidance on monitoring for ONJ or routine dental evaluations prior to or during therapy. Causation-related considerations for affected patients involve establishing a temporal relationship between Fosamax use and the development of ONJ, excluding other potential causes such as cancer, radiation therapy, or other medications known to cause ONJ. The variable onset of symptoms and the occurrence of ONJ in patients not taking bisphosphonates complicate individual causation assessments. Patients who develop ONJ while on Fosamax should be evaluated by a dental professional with experience in managing the condition, and discontinuation of the bisphosphonate may be considered based on the severity of symptoms and the patient's underlying bone health.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Fosamax (alendronate) is a bisphosphonate medication that has been associated with osteonecrosis of the jaw (ONJ), a condition where bone in the jaw becomes exposed and fails to heal. The risk is increased with invasive dental procedures, longer duration of use, and certain co-morbidities. The prescribing information includes a warning about this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).
Symptoms include exposed bone in the jaw that persists for more than eight weeks, often accompanied by pain, swelling, infection, or drainage. Diagnosis is primarily clinical, and imaging may be used to rule out other conditions. The condition can cause significant difficulty with eating, speaking, and oral hygiene.
The time to onset of symptoms can range from one day to several months after starting the drug. Most patients experience relief after stopping the medication, but symptoms may recur if rechallenged with the same or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Request archival records or inquire about member-exclusive transition and benefit programs.
Individuals with documented archive exposure and a related diagnosis may request an independent, no-cost eligibility review.